Related Experiment Videos
Meropenem in the treatment of febrile neutropenic children
Judit Müller1, Miklós Garami, Tamás Constantin
12nd Department of Pediatrics, Semmelweis University, H-1094 Budapest, Hungary. muller@gyer2.sote.hu
Abstract:
The aim of this retrospective study was to evaluate the clinical effectiveness of meropenem in immunocompromised children. Between January 1998 and December 2002 in the hemato-oncological units of our hospital meropenem was used in 87 febrile events diagnosed in 55 patients, and 328 bacterial cultures were evaluated. Microorganisms were detected and identified in 64 of the 328 hemocultures; there was a predominance of gram-positive strains (67%). In 49.4% the infection was documented microbiologically. In 16 additional cases the infection was proven clinically and 32.2% of the episodes were considered to be fever of unknown origin. The success rate of the meropenem therapy-excluding the proven fungal or coagulase-negative Staphylococcus infections--was 72.9% and for the whole cohort 49.4%. The results demonstrate that meropenem is effective and well-tolerated when used for the treatment of neutropenic cancer children.
Insights
Meropenem effectively treated infections in immunocompromised children with cancer. This antibiotic demonstrated good tolerance and clinical success rates in neutropenic patients.
Area of Science:
- Pediatric Oncology
- Infectious Diseases
- Pharmacology
Background:
- Neutropenic patients, particularly those with cancer, are highly susceptible to infections.
- Prompt and effective antibiotic therapy is crucial for managing febrile episodes in this population.
- Meropenem is a broad-spectrum carbapenem antibiotic used for serious bacterial infections.
Purpose of the Study:
- To retrospectively evaluate the clinical effectiveness and tolerability of meropenem.
- To assess meropenem's efficacy in treating febrile episodes in immunocompromised children with cancer.
Main Methods:
- Retrospective analysis of 87 febrile events in 55 immunocompromised children treated with meropenem.
- Evaluation of 328 bacterial cultures, including hemocultures.
- Assessment of infection documentation (microbiological or clinical) and treatment success rates.
Main Results:
- Gram-positive strains predominated (67%) among detected microorganisms.
- Microbiologically documented infections occurred in 49.4% of cases.
- Meropenem therapy success rate was 72.9% (excluding fungal/Staphylococcus infections) and 49.4% overall.
Conclusions:
- Meropenem is an effective and well-tolerated treatment option for neutropenic children with cancer.
- The study supports the use of meropenem in managing febrile episodes in this vulnerable patient group.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Rocky Mountain Spotted Fever
Anthelminthic Agents